Bayer rises on FY outlook hike

By Reuters News

** Shares in Bayer BAYGn.DE rise 2% in early Frankfurt trade after the German pharmaceuticals and agriculture group raised adjusted core earnings outlook for the year on the back of a better-than-expected performance at its pharma division

** Bayer expects adjusted core earnings on a currency-adjusted basis to reach between €9.8-€10.3 billion ($11-$11.5 billion) from a previously expected range of €9.6-€10.1 billion

** "Overall, we expect the results to be well received given the Pharma-driven EBITDA beat and guidance raise," J.P Morgan ("overweight") writes

** Bayer tops the German blue-chip index .GDAXI in early Frankfurt trade





($1 = 0.8937 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.